Ultime notizie per PaxMedica (OTC:PXMD) Azioni

PaxMedica

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

PaxMedica Inc

<p><strong>Blue Bird</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.</p>
<p>Revenue was up $47.25 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Blue Bird's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

BLBD

Blue Bird Earnings Analysis: Q4 Recap

<p><strong>Enanta Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.</p>
<p>Revenue was down $4.33 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.38 in the last quarter, resulting in a 1.0% increase share price change the following day.</p>
<p>Here's a look at Enanta Pharma's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ENTA

Insights into Enanta Pharma Q4 Earnings

<p>The earnings results for <strong>Central Garden &amp; Pet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) for Q4 were made public on Monday, November 25, 2024 at 04:02 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Central Garden &amp; Pet beat estimated earnings by 18.0%, reporting an EPS of $-0.18 versus an estimate of $-0.22.</p>
<p>Revenue was down $80.66 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>The company beat on EPS by $0.02 in the previous quarter, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Central Garden &amp; Pet's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.20</td>
<td>1.21</td>
<td>0.80</td>
<td>0.76</td>
<td>-0.14</td>
<td>-0.14</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.32</td>
<td>1.32</td>
<td>0.99</td>
<td>0.99</td>
<td>0.01</td>
<td>0.01</td>
<td>0.08</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.00B</td>
<td>1.00B</td>
<td>887.42M</td>
<td>883.42M</td>
<td>619.95M</td>
<td>619.95M</td>
<td>735.32M</td>
<td>735.32M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>996.35M</td>
<td>996.35M</td>
<td>900.09M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>634.53M</td>
<td>750.15M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENTA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CENTA

Central Garden & Pet Q4 Earnings Assessment

<p><strong>New Jersey Resources</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) just disclosed its Q4 earnings on Monday, November 25, 2024 at 04:30 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>New Jersey Resources beat estimated earnings by 1.0%, reporting an EPS of $0.89 versus an estimate of $0.88.</p>
<p>Revenue was up $64.45 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company missed on EPS by $0.08, leading to a 2.0% increase share price change the next day.</p>
<p>Here's a look at New Jersey Resources's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.01</td>
<td>1.32</td>
<td>0.75</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.09</td>
<td>1.41</td>
<td>0.74</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>283.00M</td>
<td>670.00M</td>
<td>662.00M</td>
<td>760.00M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>275.64M</td>
<td>657.91M</td>
<td>467.21M</td>
<td>331.32M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for New Jersey Resources <a href="https://www.benzinga.com/quote/NJR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: New Jersey Resources Q4 Earnings

<p><strong>Chegg, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) shares traded higher on Monday after the company announced a repurchase agreement for its 0% convertible senior notes due 2026. Here&#8217;s<a href="https://www.benzinga.com/quote/CHGG/news"> what you need to know.</a></p>
<p><strong>What To Know</strong>: Chegg has entered into private agreements with certain noteholders to repurchase approximately $116.6 million of its outstanding 0% convertible senior notes due 2026 for a cash price of $96.2 million. The repurchase transactions were entered into as part of Chegg's previously announced securities repurchase program.</p>
<p>The note repurchases are expected to close on Dec. 3. Following closing, $127.9 million aggregate principal amount of the notes will remain outstanding, while $207.5 million will remain available for repurchases under the program.</p>
<p>The move reduces the company's outstanding debt, which appears to have contributed to Monday&#8217;s positive market reaction. Chegg provides learning support services through its platform, offering AI-powered academic assistance and access to subject matter experts. </p>
<p>Chegg reported better-than-expected financial results for the third quarter earlier this month. Multiple analysts lowered price targets following the report, ranging from $1.50 to $3 per share. </p>
<p><strong>CHGG Price Action:</strong> Chegg shares closed Monday up 12.2% at $2.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="545" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-1024x545.png" alt="" class="wp-image-664186" style="width:459px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-1024x545.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-300x160.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG-768x409.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25153805/CHGG.png 1437w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42173927/how-rich-are-you-find-out-whether-you-rank-as-upper-middle-or-lower-class-based-on-income-and-other-factors">How Rich Are You? Find Out Whether You Rank As Upper, Middle Or Lower Class Based On Income And Other Factors</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


News

Movers

CHGG

Chegg Shares Rallied On Monday: What Happened?

<p><strong>Tesla Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares closed lower on Monday. Reports indicate Tesla vehicles would not be eligible for rebates under a new California <a href="https://www.benzinga.com/news/24/07/39846836/california-ev-subsidies-made-tesla-what-it-is-but-elon-musk-is-ready-to-cut-them-off-remove-subsidie">consumer rebates proposal</a>.</p>
<p><strong>What Happened:</strong> According to a Bloomberg <a href="https://www.bloomberg.com/news/articles/2024-11-25/california-pledges-ev-buyer-rebate-if-trump-kills-7-500-credit?sref=TBDibEcD&amp;embedded-checkout=true">report</a>, California Governor <strong>Gavin Newsom</strong> outlined new plans on Monday to offer incentives for EV buyers in California if President-elect <strong>Donald Trump</strong> gets rid of the current federal $7,500 tax break for EV buyers when he returns to the White House early next year.</p>
<p>Newsom&#8217;s team reportedly told Bloomberg that the new proposal includes &#8220;market-share limitations&#8221; that would exclude Tesla&#8217;s EV models from tax credit eligibility.</p>
<p>"It's about creating the market conditions for more of these car makers to take route,"&nbsp;the governor&#8217;s office reportedly said.</p>
<p>Tesla CEO <strong>Elon Musk</strong> and Newsom have a &#8220;tense&#8221; relationship dating back to before Musk decided to move Tesla&#8217;s headquarters out of California. Musk pushed back against state orders to close the company&#8217;s factory during the COVID-19 pandemic, calling them &#8220;fascist.&#8221; Newsom reportedly said Tesla owed some of its success to California.</p>
<p>The news follows reports from earlier this month indicating that Trump's team plans to kill the $7,500 EV tax credit on vehicle purchases as part of a broader tax-reform plan.</p>
<p><strong>See Also: <a href="https://www.benzinga.com/government/regulations/24/11/42160725/tesla-faces-environmental-violations-as-elon-musks-doge-prepares-for-garbage-collection-of-rules-that-dont-make-sense-report">Tesla Faces Environmental Violations As Elon Musk&#8217;s &#8216;DOGE&#8217; Prepares For &#8216;Garbage Collection Of Rules That Don&#8217;t Make Sense:&#8217; Report</a></strong></p>
<p>Musk reportedly told Trump's team that he supports <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">putting an end to the EV tax credit</a>. The Tesla CEO said earlier this year that removing the EV tax credit could have a slight impact on Tesla sales, but would be far worse for Tesla&#8217;s U.S.-based competitors. Analysts seem to agree.</p>
<p>Wedbush analyst&nbsp;<strong>Dan Ives</strong>&nbsp;said in a note following the news that the cuts are actually&nbsp;<a href="https://www.benzinga.com/trading-ideas/24/11/41985486/if-tesla-stock-hits-all-time-highs-in-2025-will-it-be-driven-by-trump-musk-relationship-benzinga-readers-say-this" target="_blank" rel="noreferrer noopener">net positive for Tesla</a>. The Wedbush analyst acknowledged that getting rid of the tax credit could weigh on demand, but he believes it will actually propel Tesla further ahead of competitors.&nbsp;</p>
<p>"We expect Musk to have a big seat at the table as these EV discussions happen within the Trump transition team. We believe any sell-off in Tesla from these reports is the wrong knee-jerk reaction and we would be buyers," Ives said in a recent Tesla note.</p>
<p>UBS analyst Joseph Spak maintained Tesla with a <a href="https://www.benzinga.com/analyst-stock-ratings">Sell rating</a> on Monday and raised the price target from&nbsp;$197&nbsp;to&nbsp;$226.</p>
<p><strong>TSLA Price Action:</strong> <a href="http://benzinga.com/quote/tsla">Tesla shares</a> are up approximately 31% over the past month. The EV stock was down 3.96% at $338.59 at the time of publication Monday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.</p>
<p><em>Photo: courtesy of Tesla.</em></p>


TSLA

What's Going On With Tesla Stock Today?

Guidance

FLNC

Fluence Energy Expects FY25 Revenue Of Approximately $3.6B - $4.4B With Midpoint Of $4.0B (Est $3.948B)

<p><strong>SMARTCELLs with integrated Veea Edge Platform offer a practical solution for collection and processing of massive amounts of data for highly unique AI-driven edge applications</strong></p>
<p>Visit our Booth #510 at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffall.smartcitiesconnect.org%2F&amp;esheet=54158095&amp;newsitemid=20241125091566&amp;lan=en-US&amp;anchor=Smart+Cities+Connect+Conference&amp;index=1&amp;md5=4b23dc81dbe3ae7ce6d4ca86d8452596">Smart Cities Connect Conference</a> in Austin, TX, December 3-5, 2024</p>
<p>MARQUEE Wireless Inc., a company specializing in integrationand deployment ofcellular, IoT andedge computing technologiesfor cellular networks and Smart Cities, and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.veea.com%2F&amp;esheet=54158095&amp;newsitemid=20241125091566&amp;lan=en-US&amp;anchor=Veea+Inc.&amp;index=2&amp;md5=76fd2ac704fd03a9954b41352a07faf3">Veea Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEA#NASDAQ">VEEA</a>), a pioneer in hyperconverged Multiaccess Edge Computing (MEC) with AI-driven cybersecurity and edge solutions, announced a partnership for a visionary initiative to roll out a transformative solution based on MARQUEE's patented SMARTCELL&#x2122; platform supported by Veea's Decentralized Physical Infrastructure Network (DePIN) to accelerate the introduction of MEC solutions with Edge AI as an extension of cellular network infrastructure.</p>


VEEA

VEEA Announces A Partnership For A Visionary Initiative To Roll Out A Transformative Solution Based On  MARQUEE's Patented SMARTCELL Platform Supported By Veea's Decentralized Physical Infrastructure Network To Accelerate The Introduction Of MEC Solutions With Edge AI As An Extension Of Cellular Network Infrastructure

<p>New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $0.88 by 1.14 percent.  The company reported quarterly sales of $395.780 million which missed the analyst consensus estimate of $407.000 million by 2.76 percent.  This is a 19.45 percent increase over sales of $331.325 million the same period last year.</p>


Earnings Beats

Earnings Misses

New Jersey Resources Q4 2024 Adj. EPS $0.89 Beats $0.88 Estimate, Sales $395.780M Miss $407.000M Estimate

Dana Announces Plan To Sell Off-Highway Business; Co. Also Initiates Cost Reduction Plan, Expecting To Deliver Annualized Savings Of ~$200M By 2026, Says Plans To Reduce Capital Spending To Reflect The Revised Market Demand For Electric Vehicles

<ul>
<li><i>Ashley Buchanan Appointed Chief Executive Officer and Board Member, Starting January 15</i></li>
<li><i>Tom Kingsbury Plans to Step Down as CEO on January 15, Retaining an Executive Advisory Role and Board Seat Through His Retirement in May 2025</i></li>
</ul>
<p>Kohl's Corporation ("Kohl's" or the "Company") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) today announced that Chief Executive Officer Tom Kingsbury plans to step down as CEO, effective January 15, 2025. He will stay on in an advisory role to the new CEO and retain his position on Kohl's Board of Directors (the "Board") through his retirement in May 2025, after which the size of the board will be reduced by one.</p>
<p>The Board has appointed retail veteran Ashley Buchanan as CEO, effective January 15. Buchanan has been CEO of Michaels Companies since 2020 and, prior to that, has held a variety of senior executive roles at Walmart and Sam's Club during his 13 years at the company.</p>


Management

Kohl's Announces CEO Transition Process; Ashley Buchanan Appointed CEO And Board Member, Starting January 15; Tom Kingsbury Plans To Step Down As CEO On January 15, Retaining An Executive Advisory Role And Board Seat Through His Retirement In May 2025

Dana Appoints Current Director R. Bruce McDonald As Chairman And CEO

<p>Universal Health Realty Income Trust (NYSE:&nbsp;UHT) announced today that its Board of Trustees voted to increase the quarterly dividend by $.005 and pay a dividend of $.735 per share on December 31, 2024 to shareholders of record as of December 16, 2024.</p>


Dividends

Universal Health Realty Income Trust Announces Dividend Increase From $0.73 To $0.735 Per Share

<p><strong>Blue Bird</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.</p>
<p>Revenue was up $47.25 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.4, resulting in a 0.0% increase change in the share price the following day.</p>
<p>Here's a look at Blue Bird's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Blue Bird Earnings Review: Q4 Summary

<p><strong>Woodward</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:00 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Woodward beat estimated earnings by 13.0%, reporting an EPS of $1.41 versus an estimate of $1.25.</p>
<p>Revenue was up $77.42 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.12 in the last quarter, resulting in a 17.0% drop share price change the following day.</p>
<p>Here's a look at Woodward's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.51</td>
<td>1.32</td>
<td>1.10</td>
<td>1.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.63</td>
<td>1.62</td>
<td>1.45</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>853.82M</td>
<td>807.00M</td>
<td>748.29M</td>
<td>765.35M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>847.69M</td>
<td>835.34M</td>
<td>786.73M</td>
<td>777.07M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Woodward management provided guidance for FY 2025, expecting earnings between $5.75 and $6.25 per share.</p>
<p>To track all earnings releases for Woodward <a href="https://www.benzinga.com/quote/WWD/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Woodward Earnings Report: Q4 Overview

<p><strong>Enanta Pharma</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.</p>
<p>Revenue was down $4.33 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.38 in the previous quarter, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Enanta Pharma's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Enanta Pharma: Q4 Earnings Insights

<p><strong>Central Garden &amp; Pet</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) announced its Q4 earnings on Monday, November 25, 2024 at 04:02 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.</p>
<p>Revenue was down $80.66 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.11, leading to a 6.0% increase share price change the next day.</p>
<p>Here's a look at Central Garden &amp; Pet's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CENT

Insights into Central Garden & Pet Q4 Earnings

<p><strong>Pennant Park Investment</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported its Q4 earnings results on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Pennant Park Investment missed estimated earnings by 0.0%, reporting an EPS of $0.22 versus an estimate of $0.22.</p>
<p>Revenue was up $2.46 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Pennant Park Investment's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.23</td>
<td>0.24</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.24</td>
<td>0.22</td>
<td>0.24</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>36.66M</td>
<td>36.34M</td>
<td>32.74M</td>
<td>34.83M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>37.00M</td>
<td>35.98M</td>
<td>34.34M</td>
<td>34.04M</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for Pennant Park Investment <a href="https://www.benzinga.com/quote/PNNT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PNNT

Recap: Pennant Park Investment Q4 Earnings

<p>The earnings results for <strong>PennantPark Floating Rate</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFLT#NYSE">PFLT</a>) for Q4 were made public on Monday, November 25, 2024 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>PennantPark Floating Rate missed estimated earnings by 0.0%, reporting an EPS of $0.32 versus an estimate of $0.32.</p>
<p>Revenue was up $19.79 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company missed on EPS by $0.01, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at PennantPark Floating Rate's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.32</td>
<td>0.31</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.31</td>
<td>0.31</td>
<td>0.33</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>45.52M</td>
<td>39.45M</td>
<td>35.01M</td>
<td>34.59M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>48.51M</td>
<td>44.35M</td>
<td>37.97M</td>
<td>35.73M</td>
</tr>
</tbody>
</table>
</p>
<p><strong> Listen to the earnings announcement yourself by <a href="">clicking here</a>. </strong></p>
<p>To track all earnings releases for PennantPark Floating Rate <a href="https://www.benzinga.com/quote/PFLT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PFLT

PennantPark Floating Rate Earnings Review: Q4 Summary

<p>The earnings results for <strong>StealthGas</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GASS#NASDAQ">GASS</a>) for Q3 were made public on Monday, November 25, 2024 at 09:10 AM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>StealthGas beat estimated earnings by 15.0%, reporting an EPS of $0.38 versus an estimate of $0.33.</p>
<p>Revenue was up $5.79 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.22 in the last quarter, resulting in a 2.0% drop share price change the following day.</p>
<p>Here's a look at StealthGas's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.53</td>
<td>0.24</td>
<td>0.30</td>
<td>0.15</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.75</td>
<td>0.53</td>
<td>0.29</td>
<td>0.16</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>39.20M</td>
<td>34.30M</td>
<td>33.90M</td>
<td>27.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>41.79M</td>
<td>41.56M</td>
<td>34.14M</td>
<td>34.65M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for StealthGas <a href="https://www.benzinga.com/quote/GASS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GASS

StealthGas Q3 Earnings Assessment

PaxMedica, Inc. (PXMD) has shared an update. PaxMedica, Inc. has released an updated corporate slide presentation on its website for use in discuss...

PaxMedica Releases Updated Investor Presentation Online

PaxMedica shares soar 125% post-market on drug update

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Friday is here and we&rsquo;re starting the final day of trading this week with a breakdown of the biggest pre-market stock movers this morning!</p>



<p>Moving stocks this morning are earnings reports, stakeholder updates, drug development news and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>PaxMedica </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/"><strong>PXMD</strong></a>) stock is rocketing close to 82% after hitting a <a href="https://www.nasdaq.com/press-release/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on">key milestone in drug development</a>.</li>



<li><strong>Allarity Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/"><strong>ALLR</strong></a>) shares are soaring more than 61% alongside heavy pre-market trading.</li>



<li><strong>Zapata Computing</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/zpta-stock-quote/"><strong>ZPTA</strong></a>) stock is surging over 36% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230226&amp;type=PDF&amp;symbol=ZPTA&amp;cdn=e948601bd73c48c35f25d9d7dd224e92&amp;companyName=Zapata+Computing+Holdings+Inc.&amp;formType=SC+13G%2FA&amp;formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-11">following a stakeholder update</a>.</li>



<li><strong>NextPlat </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/nxpl-stock-quote/"><strong>NXPL</strong></a>) shares are rising 32% alongside a <a href="https://www.nasdaq.com/press-release/nextplat-reports-consolidated-year-end-2023-results-with-increased-revenues-of-%2437.8">positive 2023 earnings report</a>.</li>



<li><strong>AMTD Digital</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/hkd-stock-quote/"><strong>HKD</strong></a>) stock is increasing more than 25% with strong early morning trading.</li>



<li><strong>Beneficient </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/benf-stock-quote/"><strong>BENF</strong></a>) shares are gaining over 25% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230412&amp;type=PDF&amp;symbol=BENF&amp;cdn=eb254668ceab70d3f25ad97304b464e9&amp;companyName=Beneficient&amp;formType=SC+13D%2FA&amp;formDescription=%5BAmend%5D+General+statement+of+acquisition+of+beneficial+ownership&amp;dateFiled=2024-04-11">a stakeholder update</a>.</li>



<li><strong>NRX Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrxp-stock-quote/"><strong>NRXP</strong></a>) stock is heading more than 18% higher <a href="https://www.nasdaq.com/press-release/nrxs-nasdaq%3a-nrxp-nmda-modification-therapy-and-its-multiple-applications-from-mental">on therapy news</a>.</li>



<li><strong>Lyell Immunopharma</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/lyel-stock-quote/"><strong>LYEL</strong></a>) shares are jumping over 15% this morning.</li>



<li><strong>Soligenix </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/sngx-stock-quote/"><strong>SNGX</strong></a>) stock is climbing more than 14% on <a href="https://www.nasdaq.com/press-release/fda-grants-soligenix-orphan-drug-designation-for-the-prevention-and-post-exposure">positive drug news</a>.</li>



<li><strong>OncoCyte </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/ocx-stock-quote/"><strong>OCX</strong></a>) shares are up over 14% with its <a href="https://ng.investing.com/news/stock-market-news/oncocyte-reports-full-year-2023-financial-results-93CH-1298708">Q4 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Motus GI</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/"><strong>MOTS</strong></a>) stock is plummeting more than 35% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230488&amp;type=PDF&amp;symbol=MOTS&amp;cdn=84b00af3974179838345280e52876622&amp;companyName=Motus+GI+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-11">on a delisting warning</a>.</li>



<li><strong>Spectaire </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/spec-stock-quote/"><strong>SPEC</strong></a>) shares are diving 17% despite a lack of news today.</li>



<li><strong>Rent the Runway</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/rent-stock-quote/"><strong>RENT</strong></a>) stock is retreating over 15% <a href="https://investorplace.com/2024/04/why-is-rent-the-runway-rent-stock-up-30-today/">after rallying yesterday</a>.</li>



<li><strong>Monogram Orthopaedics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgrm-stock-quote/"><strong>MGRM</strong></a>) shares are tumbling more than 13% as it <a href="https://www.nasdaq.com/press-release/monogram-accepted-to-nvidia-inception-program-2024-04-11">also jumped higher yesterday</a>.</li>



<li><strong>Rallybio </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/rlyb-stock-quote/"><strong>RLYB</strong></a>) stock is pulling back over 11% after a <a href="https://investorplace.com/2024/04/why-is-rallybio-rlyb-stock-up-93-today/">major rally on Thursday</a>.</li>



<li><strong>Applied Digital</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/"><strong>APLD</strong></a>) shares are falling more than 11% with its <a href="https://finance.yahoo.com/news/applied-digital-reports-fiscal-third-200500599.html">fiscal Q3 2024 earnings report</a>.</li>



<li><strong>Kazia Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/"><strong>KZIA</strong></a>) stock is taking an over 10% beating without any clear news this morning.</li>



<li><strong>MOGU </strong>(NYSE:<a href="https://investorplace.com/stock-quotes/mogu-stock-quote/"><strong>MOGU</strong></a>) shares are decreasing more than 10% with no obvious news to report.</li>



<li><strong>Marin Software</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/"><strong>MRIN</strong></a>) stock is dropping over 10% <a href="https://investorplace.com/2024/04/why-is-marin-software-mrin-stock-up-62-today/">after rallying recently</a>.</li>



<li><strong>GCT Semiconductor</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/gcts-stock-quote/"><strong>GCTS</strong></a>) shares close out our pre-market stock movers down more than 10%.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>PaxMedica&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/"><strong>PXMD</strong></a>) stock is rocketing higher on Friday after the clinical-stage biopharmaceutical company <a href="https://www.nasdaq.com/press-release/paxmedica-achieves-key-milestone-in-the-development-of-pax-101-and-provides-update-on">reached a key milestone</a> in drug development.</p>



<p>The big news here is the company securing three pivotal registration/validation batches of PAX-101. The company says that this is a key milestone in its plans for a New Drug Application (NDA) set for Q4 2024.</p>



<p>Investors are celebrating this news as it puts PAX-101 one step closer to approval from the Food and Drug Administration&nbsp;(FDA). If approved, it would be the first first and only form of suramin for the treatment of Stage 1 Human African Trypanosomiasis.</p>



<h2>What&rsquo;s Next for PXMD Stock?</h2>



<p>Howard Weisman, chairman and CEO of&nbsp;PaxMedica, said the following about the company&rsquo;s next plan for PAX-101.</p>




<p>&ldquo;The long-term vision for PaxMedica is to further clinical investigation of PAX-101 as a treatment for individuals who struggle with Autism Spectrum Disorder. With this important manufacturing milestone completed, we have removed a major impediment to testing PAX-101 as a treatment for the core symptoms of Autism Spectrum Disorder.&rdquo;</p>




<p>All of this news brings with it heavy trading of PXMD stock this morning. That has more than 5 million shares changing hands as of this writing. That&rsquo;s quite the leap over its daily average trading volume of about 240,000 shares.</p>



<p>PXMD stock is up 92.7% as of Friday morning.</p>



<p>There are more stock market stories traders need to know about on Friday!</p>



<p>Luckily, we have all of the hottest stock market news ready to go today! That starts with our biggest pre-market stock movers this morning while also catching investors up on yesterday&rsquo;s news. You can dive into all of that at the links below!</p>



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/04/5-investors-betting-big-on-rent-the-runway-rent-stock/">5 Investors Betting Big on Rent the Runway (RENT) Stock</a></li>



<li><a href="https://investorplace.com/2024/04/cantor-fitzgerald-just-raised-its-rating-on-soundhound-ai-soun-stock/">Cantor Fitzgerald Just Raised Its Rating on SoundHound AI (SOUN) Stock</a></li>
</ul><p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Why Is PaxMedica (PXMD) Stock Up 93% Today?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Allarity Therapeutics</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/"><strong>ALLR</strong></a>) stock is heading higher on Friday alongside heavy pre-market trading.</p>



<p>Investors will note that this movement comes after the company <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318229974&amp;type=PDF&amp;symbol=ALLR&amp;cdn=994a98b62336e93eb05e904c271966d1&amp;companyName=Allarity+Therapeutics+Inc.&amp;formType=424B5&amp;formDescription=Prospectus+%5BRule+424%28b%29%285%29%5D&amp;dateFiled=2024-04-11">announced a prospectus supplement</a>. This alters the maximum aggregate offering price of shares sold through prospectus from $1,350,000 to $2,350,000.</p>



<p>Allarity Therapeutics notes that it currently has 828,580 shares outstanding with a value of $7,092,593. The amendment mentions that the company has sold $1,348,908 worth of its shares and is eligible to sell $1,015,290 more.</p>



<h2>ALLR Stock Movement Today</h2>



<p>The heavy pre-market trading has more than 2.8 million shares of the clinical-stage biopharmaceutical company&rsquo;s stock changing hands. That&rsquo;s well above its daily average trading volume of about 59,000 shares.</p>



<p>Investors will also note that ALLR stock is up 41.3% as of Friday morning. Even so, the shares closed out Thursday down 78.9% since the start of the year.</p>



<p>Another thing to note is that ALLR is a penny stock. This comes from its low daily average trading volume, prior closing price of $2.30 per share and market capitalization of only $1.0821.082. All of these make it a risky investment.</p>



<p>There are even more of the most recent stock market stories traders will want to read about today below!</p>



<p>We are offering all of the hottest stock market news that investors need to know about on Friday! Among that is what has shares of <strong>PaxMedica&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/"><strong>PXMD</strong></a>) stock rising, the biggest pre-market stock movers this morning and more. All of this info is ready to go at the following links!</p>



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>



<li><a href="https://investorplace.com/2024/04/5-investors-betting-big-on-rent-the-runway-rent-stock/">5 Investors Betting Big on Rent the Runway (RENT) Stock</a></li>
</ul><p><em><strong>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Motus GI</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/"><strong>MOTS</strong></a>) stock is falling on Friday following a warning that the medical technology company is in danger of being delisted.</p>



<p>Motus GI <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318230488&amp;type=PDF&amp;symbol=MOTS&amp;cdn=84b00af3974179838345280e52876622&amp;companyName=Motus+GI+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-11">got a delisting notice</a> from the Listing Qualifications Staff of the <strong>Nasdaq Exchange</strong> on April 5. In that notice, the company was warned about a potential delisting due to its low shares price.</p>



<p>Shares of MOTS stock have been trading for less than $1 each for over 30 business days. That has the company not complying with the minimum bid to remain listed on the exchange.</p>



<p>On that same note, Motus GI has enacted reverse stock splits with a ratio of 250 shares or more to one over the last year. That makes it ineligible for a compliance period to regain the $1 minimum bid.</p>



<h2>What This Means for MOTS Stock</h2>



<p>Motus GI has until today to request a hearing with the Nasdaq Exchange to try and avoid delisting. However, the company doesn&rsquo;t believe it can regain compliance and is choosing not to seek a hearing.</p>



<p>As a result, shares of MOTS stock will stop trading on the Nasdaq Exchange when markets open on Tuesday. This will result in its shares switching over to the OTC Pink Market of the OTCMarkets. It intends to apply for listing on the OTCQB.</p>



<p>Finally, Motus GI says it is exploring a range of strategic options. Its doing so to maximize shareholder value while speeding up the commercialization of its Pure-Vu System.</p>



<p>MOTS stock is down 37.1% as of Friday morning.</p>



<p>There are more stock market stories traders are going to want to read about!</p>



<p>Fortunately, we have a full list of stock market happenings worth reading on Friday! A few examples include what&rsquo;s sending shares of <strong>Allarity Therapeutics</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/"><strong>ALLR</strong></a>) and <strong>PaxMedica&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/"><strong>PXMD</strong></a>) stock higher, as well as the biggest pre-market stock movers this morning. All of that info is available below!</p>



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-april-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul><p><em><strong>On Penny Stocks and Low-Volume Stocks:</strong>&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More:</strong>&#8239;Penny Stocks &mdash;&nbsp;</em><a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank"><em>How to Profit Without Getting Scammed</em></a></p>



<p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/why-is-motus-gi-mots-stock-down-37-today/">Why Is Motus GI (MOTS) Stock Down 37% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Why Is Motus GI (MOTS) Stock Down 37% Today?

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Applied Digital</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/apld-stock-quote/"><strong>APLD</strong></a>) stock is falling on Friday following the release of the data center company&rsquo;s earnings report for its fiscal third quarter of 2024.</p>



<p>The bad news for APLD stockholders starts with the company&rsquo;s <a href="https://finance.yahoo.com/news/applied-digital-reports-fiscal-third-200500599.html">adjusted earnings per share of -24 cents</a>. That&rsquo;s much worse than the -7 cents per share that Wall Street was expecting. It&rsquo;s also a significant setback compared to the -1 cent per share from the same period of the year prior.</p>



<p>Also not helping matters is Applied Digital&rsquo;s revenue of $43.35 million in fiscal Q3 2024. That&rsquo;s another miss next to analysts&rsquo; revenue estimate of $51.92 million. This is despite it increasing 208% year-over-year from $14.09 million.</p>



<p>Wes Cummins, chairman and CEO of Applied Digital, said this in the earnings report.</p>




<p>&ldquo;During the quarter, Applied Digital encountered several challenges that impacted our financial performance due to facility power outages in our datacenter hosting business. Despite these short-term setbacks, we made significant progress with our key growth initiatives in the development of our Cloud Services business and the establishment of our special purpose built 100 MW HPC datacenter in Ellendale.&rdquo;</p>




<h2>APLD Stock Movement Today</h2>



<p>Investors aren&rsquo;t happy about these latest earnings results from Applied Digital. That has shares of APLD stock falling 5.5% as of Friday morning. That builds on a 55.9% decrease year-to-date as of Thursday&rsquo;s close.</p>



<p>With today&rsquo;s drop in price comes roughly 216,000 shares of APLD stock changing hands. That&rsquo;s well below its daily average trading volume of about 3.5 million shares.</p>



<p>Investors will find even more of the most recent stock market news below!</p>



<p>We have all of the hottest stock market stories worth reading about on Friday! That includes what&rsquo;s going on with shares of <strong>Motus GI</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/mots-stock-quote/"><strong>MOTS</strong></a>) stock, <strong>Allarity Therapeutics</strong>&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/"><strong>ALLR</strong></a>) stock and <strong>PaxMedica&nbsp;</strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/"><strong>PXMD</strong></a>) stock this morning. All of that info is available at the following links!</p>



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/04/why-is-motus-gi-mots-stock-down-37-today/">Why Is Motus GI (MOTS) Stock Down 37% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-allarity-therapeutics-allr-stock-up-41-today/">Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?</a></li>



<li><a href="https://investorplace.com/2024/04/why-is-paxmedica-pxmd-stock-up-93-today/">Why Is PaxMedica (PXMD) Stock Up 93% Today?</a></li>
</ul><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/why-is-applied-digital-apld-stock-down-6-today/">Why Is Applied Digital (APLD) Stock Down 6% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Why Is Applied Digital (APLD) Stock Down 6% Today?

DCFC, HUSA and INDO among mid-day movers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>PaxMedica</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/pxmd-stock-quote/"><strong>PXMD</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>PaxMedica reported earnings per share of -50 cents. This was below the analyst estimate for EPS of -43 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/pxmd-stock-earnings-paxmedica-for-q1-of-2024/">PXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Comments

PaxMedica

Notizie

Ultime notizie per PaxMedica (OTC:PXMD) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO